Wall Street analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to report earnings of ($0.03) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the highest EPS estimate coming in at $0.26 and the lowest estimate coming in at ($0.19). The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.27) to ($0.68). For the next year, analysts anticipate that the company will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%. The company had revenue of $9.04 million for the quarter, compared to the consensus estimate of $7.76 million.

Several equities analysts have weighed in on the company. TheStreet lowered Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, July 16th. BidaskClub downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. ValuEngine raised Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, July 18th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $19.33.

In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $13.79, for a total value of $344,750.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $5,010,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. Millennium Management LLC raised its position in shares of Adaptimmune Therapeutics by 83.4% in the first quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock valued at $16,594,000 after purchasing an additional 672,046 shares during the period. Dorsey Wright & Associates bought a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $6,981,000. Baillie Gifford & Co. raised its position in shares of Adaptimmune Therapeutics by 18.2% in the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares during the period. JPMorgan Chase & Co. raised its position in shares of Adaptimmune Therapeutics by 786.0% in the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock valued at $2,085,000 after purchasing an additional 164,704 shares during the period. Finally, Frontier Capital Management Co. LLC bought a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $1,838,000. 59.32% of the stock is currently owned by institutional investors.

NASDAQ ADAP traded down $0.12 during trading on Tuesday, hitting $10.76. 594,791 shares of the company traded hands, compared to its average volume of 468,993. Adaptimmune Therapeutics has a 12 month low of $6.60 and a 12 month high of $14.63. The firm has a market cap of $1.02 billion, a P/E ratio of -13.45 and a beta of 1.07.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Further Reading: Day Trading

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.